Urology Pathology Services

Uroveda Institute of Urogenital Diseases, an MDL Center of Excellence, provides a comprehensive menu of pathology testing plus molecular testing for urology practices. Utilizing advanced testing, our board-certified pathologists with specialized training in urologic and cytopathology, provide rapid, reliable test results to aid in diagnosing or screening for urologic conditions.

Logo Uroveda

Each year in the United States, about 57,000 men and 18,000 women get bladder cancer, and about 12,000 men and 5,000 women die from the disease.

Uroveda provides a broad portfolio of clinical urology tests including:

  • Tissue analysis/biopsies Board Certified pathologists and expert technologists in the fields of urologic and cytopathology will evaluate bladder biopsies and perform tissue testing and analysis for the presence of abnormal cells and provide detailed diagnostic information.

  • Immunohistochemical stain – Smoothelin is a smooth muscle-specific contractile protein which is expressed only by fully differentiated smooth muscle cells. It has been reported to be a useful tool in monitoring smooth muscle cell (SMC) differentiation and may aid in the staging of bladder carcinoma.

  • Urine culture & colony counts utilize specialized media to isolate, identify and quantitate bacteria and fungus to differentiate between urinary tract infection and specimen contamination with bacterial flora.

  • Antimicrobial susceptibility is used to determine the likelihood that a particular antibiotic or antifungal drug will be effective in stopping the growth of the bacteria or fungus causing an infection and is used to guide treatment decisions.

  • Urine cytology includes the exam of urine to look for abnormal cells using routine microscopy and state-of-the-art automated UroVysion® Fluorescent In situ Hybridization (FISH) to aid in the diagnosis and monitoring of dysplastic and malignant bladder lesions.

  • Molecular Microbiology by the DNA-based Polymerase Chain Reaction (PCR) method detects the presence in urine of urogenital pathogens which can cause urinary tract and sexually transmitted infections. The UroSwab® specimen collection platform offers a superior route of pathogen detection with a high diagnostic specificity and sensitivity.

    UroSwab® Advantages:
    • One vial, multiple pathogens
    • DNA amplification via PCR technology
    • Simple & convenient specimen collection
    • High precision robotic accuracy
    • High diagnostic sensitivity & specificity
    • Specimen viability up to 5 days after collection
    • Test additions available up to 30 days after collection
    • No refrigeration required before or after collection
  • Hereditary Genetics – Hereditary Renal Cancer genetic testing may confirm a diagnosis and help guide treatment and management decisions. Identification of a disease-causing variant would also guide testing and diagnosis of at-risk relatives. Pathogenic variants in multiple genes have been implicated in hereditary renal cancer.

  • Pharmacogenomic testing, using state-of-the-art Next Generation Sequencing (NGS) technology, evaluates an individual’s genetic makeup to predict how an individual responds to drugs based on their genetic variability. It provides information about genetic influences on the dosing, toxicities, and efficacy of specific drugs.

Prostate cancer is the second most common cancer among men in the United States and is also one of the leading causes of cancer death among men of all races and Hispanic origin populations.

Uroveda provides a broad portfolio of tests to assist in the diagnosis and staging of prostate cancer including:

  • Tissue analysis/biopsies Board Certified pathologists and expert technologists will evaluate prostate biopsies and perform tissue testing and analysis for the presence of abnormal cells and provide detailed diagnostic information.

  • Immunohistochemical stain – PIN4 incorporates a triple stain that is useful in distinguishing prostatic adenocarcinoma from benign conditions.

  • Hereditary Genetics – Hereditary Prostate Cancer genetic testing analyzes genes associated with a hereditary predisposition to prostate cancer. Men with pathogenic variants in these genes have an increased risk of developing prostate cancer and, in some cases, other cancers as well.

  • Pharmacogenomic testing, using state-of-the-art Next Generation Sequencing (NGS) technology, evaluates an individual’s genetic makeup to predict how an individual responds to drugs based on their genetic variability. It provides information about genetic influences on the dosing, toxicities, and efficacy of specific drugs.